Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1992-08-20
1995-05-16
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424 7835, 424438, 424468, 424487, 526306, 526307, A61K 948, A61F 902
Patent
active
054158648
ABSTRACT:
Colonic-targeted oral drug dosage forms composed of a drug confined within a crosslinked hydrogel that exhibits pH-dependent swelling and is composed of an ionizable comonomer such as acrylic acid, a nonionizable comonomer such as an acrylamide, and a crosslinking agent that contains an aromatic azobond. Selective drug release in the colon occurs by a combination of pH-dependent swelling of the hydrogel and degradation of the hydrogel by enzymatic cleavage of the azobonds by azoreductases.
REFERENCES:
patent: 4190716 (1980-02-01), Parkinson et al.
patent: 4432966 (1984-02-01), Zietoun et al.
patent: 4489197 (1984-12-01), Wang et al.
patent: 4496553 (1985-06-01), Halskov
patent: 4663308 (1987-05-01), Jaffron et al.
patent: 4971790 (1990-11-01), Magruder et al.
patent: 5078994 (1992-01-01), Mair
Hydrogels for Medical and Related Applications pp. 37-51 (Refojo) 1975.
"Isomerization . . . Effect" Eisenbach Polymer, 1980 vol. 21 (1175-1179).
Siegel et al. J. of Controlled Release 8 (1988) 179-182.
Porter, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa, 17th Edition (1985) pp. 1633-1643.
Brondsted Helle
Kim Sung W.
Kopecek Jindrich
Kopeckova Pavla
Kulkosky Peter F.
Page Thurman K.
University of Utah Research Foundation
LandOfFree
Colonic-targeted oral drug-dosage forms based on crosslinked hyd does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Colonic-targeted oral drug-dosage forms based on crosslinked hyd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Colonic-targeted oral drug-dosage forms based on crosslinked hyd will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-636382